|
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
||
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
$0.0001 par value per share
|
|
The
(Nasdaq Global Select Market)
|
●
|
address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by providing that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has, or is part of a group that has, complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including applicable notice and solicitation requirements;
|
●
|
update disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act); and
|
●
|
require that a stockholder directly or indirectly soliciting proxies from other stockholders use a proxy card color other than white.
|
(d)
|
Exhibits
|
Exhibit No.
|
Description
|
3.1
|
Amended and Restated Bylaws of Zevra Therapeutics, Inc. |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
Zevra Therapeutics, Inc.
|
|
|
|
|
|
Date: February 28, 2024
|
|
By:
|
/s/ Timothy J. Sangiovanni
|
|
|
|
Timothy J. Sangiovanni, CPA
|
|
|
|
Senior Vice President, Corporate Controller
|